DNA-PK Inhibitor II NU7026, also known as NU-7026, is a small molecule inhibitor of DNA-dependent protein kinase (DNA-PK). This product is a white to off-white powder with the chemical formula C21H18N2O2 and a molecular weight of 334.38 g/mol. Its CAS number is 154447-35-5.
Top ten keywords from Google and synonyms
Synonyms:
Health benefits of DNA-PK Inhibitor II NU7026
DNA-PK inhibitor II NU7026 has shown potential health benefits in various areas such as cancer therapy, radiosensitization, and overcoming chemotherapy resistance.
Cancer Therapy: NU7026 has been reported to have a potent anti-tumor effect in various types of cancers such as breast cancer, prostate cancer, and colon cancer. The mechanism behind its efficacy is due to its ability to inhibit DNA-PK, which plays a crucial role in the repair of double-strand breaks (DSBs) in DNA. Therefore, the inhibition of this enzyme leads to an accumulation of DNA damage and cell death.
Radiosensitizer: NU7026 has been shown to enhance the sensitivity of cancer cells to radiation by inhibiting the repair of DSBs. The combination of NU7026 and radiation therapy translates to a more effective treatment for cancer patients without the need for increased radiation dosage, thus minimizing the risk of side effects.
Overcoming Chemotherapy Resistance: NU7026 has been reported to overcome chemotherapy resistance by downregulating the expression of ATP-binding cassette (ABC) transporters such as MDR1 and ABCG2. These transporters are responsible for exporting chemotherapeutic drugs out of the cancer cells, leading to reduced effectiveness of chemotherapy. The inhibition of these transporters increases the intracellular concentration of the chemotherapeutic drug, thus enhancing its cytotoxic effect.
Potential Effects
DNA-PK inhibitor II NU7026 has shown a potent anti-tumor effect and enhanced sensitivity to radiation therapy. It has also shown promise in overcoming chemotherapy resistance, suggesting its potential application in a wide range of cancer treatments.
Product Mechanism
As an inhibitor of DNA-PK, NU7026 prevents the repair of DSBs in DNA, leading to an accumulation of DNA damage and eventual cell death. Additionally, it has been shown to downregulate ABC transporters, increasing the effectiveness of chemotherapeutic drugs.
Safety
While NU7026 has shown promising results in preclinical studies, further investigation into its safety in humans is required. Animal studies have not shown significant adverse effects, but more research is needed to fully understand its safety profile.
Side Effects
Currently, there is limited information regarding the side effects of NU7026. However, as with any medication, caution should be taken, and patients should consult with their healthcare provider before use.
Dosing Information
Dosing information for NU7026 is not yet established. Further study is necessary to determine safe and effective dosing guidelines.
Conclusion
DNA-PK inhibitor II NU7026 has shown significant potential as a therapeutic agent in various fields of medicine, particularly in cancer therapy. Its mechanism of action in inhibiting DNA-PK provides a novel approach to halting the progression of cancer. While more research is needed to establish safety and dosing guidelines for human use, NU7026 shows promise as a potential treatment option. Its ability to enhance the effectiveness of current therapies such as radiation and chemotherapy suggests that it may play an important role in future cancer treatments
